JP MORGAN/PUT/VERTEX PHARMACEUTICALS/310/0.1/17.01.25 | Market Closed - Börse Stuttgart 02:49:43 2024-06-07 EDT | ||
| 0.2 EUR | -9.09% |
|
| Current month | -55.56% | ||
| 1 month | -71.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 0.2 | -9.09% |
| 24-06-06 | 0.22 | -12.00% |
| 24-06-05 | 0.25 | -7.41% |
| 24-06-04 | 0.27 | -20.59% |
| 24-06-03 | 0.34 | -24.44% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 02:49 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL09QA |
| ISIN | DE000JL09QA0 |
| Date issued | 2023-04-12 |
| Strike | 310 $ |
| Maturity | 2025-01-17 (223 Days) |
| Parity | 10 : 1 |
| Emission price | 3.66 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.35 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.5 € |
| Spread % | 69.44% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
